Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: Purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): Results of Japanese phase II study

Y. Imai, T. Chou, K. Tobinai, R. Tanosaki, Y. Morishima, M. Ogura, C. Shimazaki, M. Taniwaki, A. Hiraoka, M. Tanimoto, T. Koike, K. Kogawa, H. Hirai, T. Yoshida, K. Tamura, K. Kishi, T. Hotta

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The purging efficacy of positive selection of autologous CD34+ PBSC with a clinical scale method of magnetic-activated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin's lymphoma (NHL). The median purity and recovery rate of the CD34+ cells post-selection were 93.3% (range 32.6-99.3) and 72.2% (range 20.5-309.8), respectively. The real-time PCR method to detect the patient-specific monoclonal immunoglobulin heavy chain gene rearrangement (minimal residual tumor; MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34+ selection. After selection, the median (range) depletion rate of MRT was 2.53 (1.52-4.78) log, and that of CD19+ cell and CD20+ cell was 2.46 (0.74-3.64) log and 2.32 (0.40-4.01) log, respectively. In 41 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34+ cells. Rapid neutrophil recovery as well as platelet recovery was seen with a median time to reach 0.5 × 109/1 neutrophils of 10 days (range 8-13) and 20 × 109/1 platelets of 14 days (range 10-34), respectively. The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy.

Original languageEnglish
Pages (from-to)479-487
Number of pages9
JournalBone Marrow Transplantation
Volume35
Issue number5
DOIs
Publication statusPublished - Mar 2005

Fingerprint

Non-Hodgkin's Lymphoma
Stem Cells
Transplantation
Neutrophils
Blood Platelets
Immunoglobulin Heavy Chain Genes
Drug Therapy
Gene Rearrangement
Residual Neoplasm
Real-Time Polymerase Chain Reaction
Transplants

Keywords

  • Autologous PBSCT
  • CD34 selection
  • High-dose chemotherapy
  • Magnetic-activated cell sorting system
  • Non-Hodgkin's lymphoma
  • Phase II study

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells : Purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): Results of Japanese phase II study. / Imai, Y.; Chou, T.; Tobinai, K.; Tanosaki, R.; Morishima, Y.; Ogura, M.; Shimazaki, C.; Taniwaki, M.; Hiraoka, A.; Tanimoto, M.; Koike, T.; Kogawa, K.; Hirai, H.; Yoshida, T.; Tamura, K.; Kishi, K.; Hotta, T.

In: Bone Marrow Transplantation, Vol. 35, No. 5, 03.2005, p. 479-487.

Research output: Contribution to journalArticle

Imai, Y, Chou, T, Tobinai, K, Tanosaki, R, Morishima, Y, Ogura, M, Shimazaki, C, Taniwaki, M, Hiraoka, A, Tanimoto, M, Koike, T, Kogawa, K, Hirai, H, Yoshida, T, Tamura, K, Kishi, K & Hotta, T 2005, 'Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: Purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): Results of Japanese phase II study', Bone Marrow Transplantation, vol. 35, no. 5, pp. 479-487. https://doi.org/10.1038/sj.bmt.1704819
Imai, Y. ; Chou, T. ; Tobinai, K. ; Tanosaki, R. ; Morishima, Y. ; Ogura, M. ; Shimazaki, C. ; Taniwaki, M. ; Hiraoka, A. ; Tanimoto, M. ; Koike, T. ; Kogawa, K. ; Hirai, H. ; Yoshida, T. ; Tamura, K. ; Kishi, K. ; Hotta, T. / Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells : Purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): Results of Japanese phase II study. In: Bone Marrow Transplantation. 2005 ; Vol. 35, No. 5. pp. 479-487.
@article{29e31fc67100470ebe1d2af10e6a37c1,
title = "Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: Purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): Results of Japanese phase II study",
abstract = "The purging efficacy of positive selection of autologous CD34+ PBSC with a clinical scale method of magnetic-activated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin's lymphoma (NHL). The median purity and recovery rate of the CD34+ cells post-selection were 93.3{\%} (range 32.6-99.3) and 72.2{\%} (range 20.5-309.8), respectively. The real-time PCR method to detect the patient-specific monoclonal immunoglobulin heavy chain gene rearrangement (minimal residual tumor; MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34+ selection. After selection, the median (range) depletion rate of MRT was 2.53 (1.52-4.78) log, and that of CD19+ cell and CD20+ cell was 2.46 (0.74-3.64) log and 2.32 (0.40-4.01) log, respectively. In 41 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34+ cells. Rapid neutrophil recovery as well as platelet recovery was seen with a median time to reach 0.5 × 109/1 neutrophils of 10 days (range 8-13) and 20 × 109/1 platelets of 14 days (range 10-34), respectively. The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy.",
keywords = "Autologous PBSCT, CD34 selection, High-dose chemotherapy, Magnetic-activated cell sorting system, Non-Hodgkin's lymphoma, Phase II study",
author = "Y. Imai and T. Chou and K. Tobinai and R. Tanosaki and Y. Morishima and M. Ogura and C. Shimazaki and M. Taniwaki and A. Hiraoka and M. Tanimoto and T. Koike and K. Kogawa and H. Hirai and T. Yoshida and K. Tamura and K. Kishi and T. Hotta",
year = "2005",
month = "3",
doi = "10.1038/sj.bmt.1704819",
language = "English",
volume = "35",
pages = "479--487",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells

T2 - Purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): Results of Japanese phase II study

AU - Imai, Y.

AU - Chou, T.

AU - Tobinai, K.

AU - Tanosaki, R.

AU - Morishima, Y.

AU - Ogura, M.

AU - Shimazaki, C.

AU - Taniwaki, M.

AU - Hiraoka, A.

AU - Tanimoto, M.

AU - Koike, T.

AU - Kogawa, K.

AU - Hirai, H.

AU - Yoshida, T.

AU - Tamura, K.

AU - Kishi, K.

AU - Hotta, T.

PY - 2005/3

Y1 - 2005/3

N2 - The purging efficacy of positive selection of autologous CD34+ PBSC with a clinical scale method of magnetic-activated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin's lymphoma (NHL). The median purity and recovery rate of the CD34+ cells post-selection were 93.3% (range 32.6-99.3) and 72.2% (range 20.5-309.8), respectively. The real-time PCR method to detect the patient-specific monoclonal immunoglobulin heavy chain gene rearrangement (minimal residual tumor; MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34+ selection. After selection, the median (range) depletion rate of MRT was 2.53 (1.52-4.78) log, and that of CD19+ cell and CD20+ cell was 2.46 (0.74-3.64) log and 2.32 (0.40-4.01) log, respectively. In 41 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34+ cells. Rapid neutrophil recovery as well as platelet recovery was seen with a median time to reach 0.5 × 109/1 neutrophils of 10 days (range 8-13) and 20 × 109/1 platelets of 14 days (range 10-34), respectively. The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy.

AB - The purging efficacy of positive selection of autologous CD34+ PBSC with a clinical scale method of magnetic-activated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin's lymphoma (NHL). The median purity and recovery rate of the CD34+ cells post-selection were 93.3% (range 32.6-99.3) and 72.2% (range 20.5-309.8), respectively. The real-time PCR method to detect the patient-specific monoclonal immunoglobulin heavy chain gene rearrangement (minimal residual tumor; MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34+ selection. After selection, the median (range) depletion rate of MRT was 2.53 (1.52-4.78) log, and that of CD19+ cell and CD20+ cell was 2.46 (0.74-3.64) log and 2.32 (0.40-4.01) log, respectively. In 41 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34+ cells. Rapid neutrophil recovery as well as platelet recovery was seen with a median time to reach 0.5 × 109/1 neutrophils of 10 days (range 8-13) and 20 × 109/1 platelets of 14 days (range 10-34), respectively. The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy.

KW - Autologous PBSCT

KW - CD34 selection

KW - High-dose chemotherapy

KW - Magnetic-activated cell sorting system

KW - Non-Hodgkin's lymphoma

KW - Phase II study

UR - http://www.scopus.com/inward/record.url?scp=20144367074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144367074&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704819

DO - 10.1038/sj.bmt.1704819

M3 - Article

C2 - 15654349

AN - SCOPUS:20144367074

VL - 35

SP - 479

EP - 487

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -